Rankings
▼
Calendar
REGN Q3 2016 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$80B
Q3 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.2B
Gross Profit
$1.1B
94.1% margin
Operating Income
$363M
29.7% margin
Net Income
$265M
21.7% margin
EPS (Diluted)
$2.27
QoQ Revenue Growth
+0.6%
Cash Flow
Operating Cash Flow
$651M
Free Cash Flow
$532M
Stock-Based Comp.
$131M
Balance Sheet
Total Assets
$6.8B
Total Liabilities
$2.3B
Stockholders' Equity
$4.5B
Cash & Equivalents
$920M
Revenue Segments
Antibody Collaboration
$88M
61%
Immuno-oncology Agreement
$56M
39%
← FY 2016
All Quarters
Q4 2016 →
